TPTX
Price:
$75.49
Market Cap:
$0
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advan...[Read more]
Industry
Biotechnology
IPO Date
2019-04-17
Stock Exchange
NASDAQ
Ticker
TPTX
According to Turning Point Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -13.55. This represents a change of 69.48% compared to the average of -7.99 of the last 4 quarters.
The mean historical PE Ratio of Turning Point Therapeutics, Inc. over the last ten years is -20.83. The current -13.55 PE Ratio has changed 6.40% with respect to the historical average. Over the past ten years (40 quarters), TPTX's PE Ratio was at its highest in in the March 2022 quarter at -4.47. The PE Ratio was at its lowest in in the September 2020 quarter at -52.04.
Average
-20.83
Median
-20.83
Minimum
-31.64
Maximum
-8.24
Discovering the peaks and valleys of Turning Point Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 51.87%
Maximum Annual PE Ratio = -8.24
Minimum Annual Increase = -73.97%
Minimum Annual PE Ratio = -31.64
Year | PE Ratio | Change |
---|---|---|
2021 | -8.24 | -73.97% |
2020 | -31.64 | 51.87% |
2019 | -20.83 | 19.61% |
2018 | -17.42 | -33.05% |
The current PE Ratio of Turning Point Therapeutics, Inc. (TPTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-20.24
5-year avg
-20.83
10-year avg
-20.83
Turning Point Therapeutics, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Turning Point Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Turning Point Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Turning Point Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Turning Point Therapeutics, Inc. (TPTX)?
What is the highest PE Ratio for Turning Point Therapeutics, Inc. (TPTX)?
What is the 3-year average PE Ratio for Turning Point Therapeutics, Inc. (TPTX)?
What is the 5-year average PE Ratio for Turning Point Therapeutics, Inc. (TPTX)?
How does the current PE Ratio for Turning Point Therapeutics, Inc. (TPTX) compare to its historical average?